Mycophenolate mofetil in cardiac transplantation

Current Opinion in Cardiology

Volumn 13, Issue 2, 1998, Pages 117-121

  Kobashigawa, Jon A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; KIDNEY GRAFT REJECTION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL;

EID: 0031969371     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199803000-00008     Document Type: Review

References (30)

1. Gosio B: Ricerche bacterlologiche e chimiche sulle alterazioni del mais. Riv Igiene Sanita Pubblica 1896, 7:825-868.
2. Abraham EP: The effect of mycophenolic acid on the growth of Staphylococcus aureus in heart broth. Biochem J 1945, 39:398-405.
3. Florey HW, Gilliver K, Jennings MA, Sanders AG: Mycophenolic acid: an antibiotic from Penicillium brevicompactum. Lancet 1946, 1:46-49.
4. Williams RH, Lively DH, DeLong DC, Cline JC, Sweeney MJ: Mycophenolic acid: antiviral and antitumor properties. J Antibiot 1968, 21:463-464.
5. Carter SB, Franklin TJ, Jones DF, Leonard BJ, Mills SD, Turner RW, Turner WB: Mycophenolic acid: an anticancer compound with unusual properties. Nature 1969, 223:848-850.
6. Suzuki S, Kimura T, Ando K, Sawada M, Tamura G: Antitumor activity of mycophenolic acid. J Antibiot 1969, 22:297-302.
7. Brewm TB, Cole MP, Jones CT, Platt DS, Todd ID: Mycophenolic acid (NSC-129185): preliminary clinical trials. Cancer Chemother Rep 1972 56:83-87.
8. Knudtzon S, Nissen NI: Clinical trial with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep 1972, 56:221-227.
9. Lintrup J, Hyltoft-Petersen P, Knudtzon S, Nissen NI: Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep 1972, 56:229-235.
10. Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG: Mycophenolate mofetil (RS-61443): predinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant 1994, 13:571-582.
11. Eugui EM, Mirkovich A, Allison AC: Lymphocyte-selective anti-proliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991, 33:175-183.
12. Eugui EM, Almquist S, Muller CD, Allison AC: Lymphocyte-selective, cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991, 33:161-173.
13. Allison AC, Hovi T, Watts RW, Webster AD: The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 1977, 48:207-224.
14. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ: Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972, 2:1067-1069.
15. Morris RE, Wang J, Blum JR, Flavin T, Murphy MP, Almquist SJ, Chu N, Tam YL, Kaloostian M, Allison AC, et al.: Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 1991, 23:19-25.
16. Steele DM, Hullett DA, Bechstein WO, Kowalski J, Smith LS, Kennedy E, Allison AC, Sollinger HW: Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993, 25:700-701.
17. Gregory C, Morris RE, Pratt R, Billingham M, Shorthouse R: The use of the new antiproliferative immunosuppressants is a novel and highly effective strategy for the prevention of vascular occlusive disease [abstract]. J Heart Lung Transplant 1992, 11:197.
18. Sollinger HW, Deierhoi MH, Beizer FO, Diethelm AG, Kauffman RS: RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992, 53:428-432.
19. Allison AC, Kowalski WJ, Muller CD, Eugui EM: Mechanism of action of mycophenolic acid. Ann NY Acad Sci 1990, 696:63-87.
20. Young CJ, Sollinger HW: RS-61443: a new immunosuppressive agent. Transplant Proc 1994, 26:3144-3146.
21. Alisson AC, Wugui EM: Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant 1993, 7:96-112.
22. Lowe JK, Brox L, Henderson JF: Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole. Cancer Res 1977, 37:736-743.
23. CellCept package insert. Nutley, NJ: Roche Laboratories, 1995 May.
24. Sweeney MJ, Hoffman DH, Esterman MA: Metabolism and biochemistry of mycophenolic acid. Cancer Res 1972, 32:1803-1809.
25. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH: Bioavailability improvement of mycophenolic acid through amino ester derivitization. Pharm Res 1990, 7:161-166.
26. Ensley RD, Bristow MR, Olsen SL, Taylor DO, Hammond EH, O'Connell JB, Dunn D, Osburn L, Jones KW, Kauffman RS, et al.: The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993, 56:75-82.
27. Kobashigawa JA, Renlund DG, Olsen SL, Stevenson LW, McDiarmid SV, Swanson S, Albanese E, Taylor DO, Dunn D, Brownfield E, et al.: Initial results of RS-61443 for refractory cardiac rejection [abstract]. J Am Coll Cardiol 1992, 19:203A.
28. Kirklin JK, Bourge RC, Naftel DC, Morrow WK, Deierhoi MH, Kauffman RS, White-Williams C, Nomberg RI, Holman WI, Smith DC Jr: Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994, 13:444-450.
29. Costanzo MR. Mycophenolate Mofetil Study Investigators: Results of the randomized trial of mycophenolate mofetil vs azathioprine in heart transplantation [abstract]. American Society for Transplant Physicians, 15th Annual Scientific Meeting, May 10-14, 1997, Chicago, IL. This abstract reviewed the results of the large, double-blind, randomized trial of mycophenolate mofetil versus azathioprine in primary prevention. Explanation of the details of this large, randomized trial are pending final publication of the manuscript.
30. Meiser BM, Jagiello-Kraatz M, Pfeiffer M, Uberfuhr P, von Scheidt W, Schmidt D, Schulze C, Wildhirt S, Reichenspurner H, Kreuzer E, Reichart B: The efficacy of mycophenolate mofetil treatment after heart transplantation is highly dependent on mycophenolate trough levels [abstract]. Circulation 1997, 96(8):1-64. This very important paper suggests that there is a threshold at which mycophenolate mofetil has its beneficial effects.